Taysha reports new TSHA-120 data analysis supports FDA path; TSHA-102 first patient dosed

Taysha Gene Therapies, Inc.

New TSHA-120 analysis shows 99% probability of slowing disease progression on mFARS and MFM32 Domain 3; FDA meeting expected Q3 2023.
First adult patient with Rett syndrome dosed with TSHA-102 in REVEAL Phase 1/2 trial; safety/efficacy update expected early Q3 2023.
CTA submission for TSHA-102 in pediatric Rett patients in UK mid-2023; IND submission to FDA H2 2023.
Over seven years of safety data support TSHA-120; DPM using natural history data supports external control for regulatory path.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.